Table 1 Clinical and pathological characteristics of reported cases of isolated oral MALT lymphoma without autoimmune or infection diseases
Case | References | Country | Age (years) | Sex | Site | CD5 | Light chain | Clinical manifestation | Involvement MSG | Management | Recurrence | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Κ | λ | |||||||||||
1 | Iftikhar et al. [40] | Pakistan | 61 | M | BoT | + | NK | NK | Dysphagia | − | CT | − |
2 | Song et al. [41] | Korea | 29 | F | BoT | NK | NK | NK | Mass involving T lymphoma history | − | RT | − |
3 | Gotri et al. [42] | Italy | 80 | F | BoT | + | + | − | Dysphagia | − | SR | − |
4 | Ferry et al. [33] | USA | 62 | F | BoT | + | − | + | Mass | − | NK | Spread |
5 | Kojima et al. [14] | Japan | 51 | M | SP | − | + | − | ND | + | SR | − |
6 |  |  | 60 | M | BM | − | − | − | ND | − | SR + RT | − |
7 |  |  | 64 | F | SP | − | + | − | ND | + | SR | + |
8 |  |  | 78 | F | Ging | − | − | − | ND | − | RT | − |
9 |  |  | 83 | M | Ging | − | − | − | ND | − | CT | + |
10 | Sakabe et al. [43] | Japan | 61 | F | BoT | + | NK | NK | Mass | + | SR | − |
11 | Ayers et al. [44] | USA | 64 | F | HP | NK | NK | NK | Mass | + | NK | NK |
12 | Bombeccari et al. [45] | Italy | 11 | M | LL | − | + | NK | Swelling | − | SR | − |
13 | Kojima et al. [46] | Japan | 78 | F | BM | − | − | + | Swelling | − | NK | NK |
14 | Kolokotronis et al. [47] | Greece | 68 | M | Ts | NK | NK | NK | NK | NK | SR + CT | + |
15 | Â | Â | 73 | F | HP | NK | NK | NK | NK | NK | SR | + |
16 | Â | Â | 48 | F | Ts | NK | NK | NK | NK | NK | SR | + |
17 | Crandley et al. [48] | USA | 9 | F | LL | NK | − | + | Swelling | + | SR | − |
18 | Frazier et al. [49] | USA | 50 | M | UL | − | + | − | Swelling | + | SR | − |
19 | Abe et al. [50] | Japan | 64 | F | HP | + | + | + | Swelling | − | SR + RT + CT | NK |
20 | Berrebi et al. [51] | France | 10 | M | LL | NK | NK | NK | Mass | + | SR | − |
21 | Eder [52] | UK | 52 | M | FoM | NK | NK | NK | Mass | NK | SR | − |
22 | Gabali et al. [53] | USA | 11 | M | LL | − | − | − | Swelling | + | SR | NK |
23 | Ruy et al. [54] | Korea | 7 | F | LL | − | + | − | Mass |  | CT | − |
24 | Japan | 66 | F | BM | + | + | + | Swelling | − | SR | − | |
25 | Gerami [55] | USA | 57 | F | LL, To then UL | − | NK | NK | Swelling | − | CT | + |
26 | Honda et al. [56] | Japan | 71 | F | FOM | NK | + | NK | Swelling | NK | RT | − |
27 | Kaplan et al. [57] | Israel | 59 | F | LL | − | NK | NK | NK | + | CT + anti-CD20 | − |
|  |  |  | 87 | F | LL | − | NK | NK | Mass | + | SR | − |
|  |  |  | 82 | F | UL | − | NK | NK | Mass | + | SR | − |
|  |  |  | 82 | F | LL | − | NK | NK | Mass | + | SR | − |
|  |  |  | 66 | F | LL | − | NK | NK | Mass | + | SR | − |
|  |  |  | 71 | F | UL and later LL | − | NK | NK | Mass | − | SR | − |
33 | Kawasaki et al. [58] | Japan | 27 | M | UL and LL | NK | NK | NK | Mass | + | SR | − |
34 | Song et al. [59] | Korea | 29 | F | BoT | − | NK | NK | Mass |  | RT | − |
35 | Mo et al. [60] | USA | 12 | M | LL | − | + | − | Mass | + | CT | − |
36 | Zehani et al. [61] | Tunis | 28 | F | Cheek | − | + | − | Swelling | − | NK | NK |
37 | Zambrano et al. [62] | USA | 14 | M | UL | − | + | + | Mass | NK | NK | NK |
38 | Urano et al. [63] | Japan | 62 | F | Cheek | NK | − | + | Swelling |  | RT + anti-CD20 | − |
39 | Ma et al. [64] | China | 59 | F | Ts | − | − | − | Swelling | − | SR + RT | − |
40 | Manveen et al. [65] | India | 40 | M | HP | + | NK | NK | Swelling | − | SR | − |
41 | Bianco et al. [66] | Italy | 82 | M | UL | − | NK | NK | Swelling | − | CT + RT | − |
42 | Tauber et al. [67] | Germany | 71 | F | HP | NK | NK | NK | Mass | NK | SR | − |